EU cites cosmetic trade issues
This article was originally published in The Rose Sheet
Executive Summary
Lack of progress on cosmetics regulatory cooperation between the EU and U.S. is viewed as potential trade barrier in the European Union's Report on U.S. Barriers to Trade and Investment released by the European Commission Dec. 19. Colour Index nomenclature for color additive labeling is cited as particular concern, as no progress has been made on industry requests to allow European-derived CI numbers in place of FDA-required nomenclature in the U.S. "The EU harmonized the majority of its labeling system with the U.S. nomenclature system, the major difference being the colour identifications used," the EU points out, adding, "FDA should act on the petition and develop a proposal for public comment." Admission of European sunscreen products into the U.S. market also is cited as a concern, as well as labeling requirements for OTC sunscreens...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.